Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system.

Jaïs PH, Decroly E, Jacquet E, Le Boulch M, Jaïs A, Jean-Jean O, Eaton H, Ponien P, Verdier F, Canard B, Goncalves S, Chiron S, Le Gall M, Mayeux P, Shmulevitz M.

Nucleic Acids Res. 2019 Mar 18;47(5):2681-2698. doi: 10.1093/nar/gkz069.

2.

Plasmodium falciparum gametocyte-infected erythrocytes do not adhere to human primary erythroblasts.

Neveu G, Dupuy F, Ladli M, Barbieri D, Naissant B, Richard C, Martins RM, Lopez-Rubio JJ, Bachmann A, Verdier F, Lavazec C.

Sci Rep. 2018 Dec 14;8(1):17886. doi: 10.1038/s41598-018-36148-y.

3.

Finely-tuned regulation of AMP-activated protein kinase is crucial for human adult erythropoiesis.

Ladli M, Richard C, Aguilar LC, Ducamp S, Bondu S, Sujobert P, Tamburini J, Lacombe C, Azar N, Foretz M, Zermati Y, Mayeux P, Viollet B, Verdier F.

Haematologica. 2019 May;104(5):907-918. doi: 10.3324/haematol.2018.191403. Epub 2018 Oct 11.

4.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

5.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.

Pasquier F, Marty C, Balligand T, Verdier F, Grosjean S, Gryshkova V, Raslova H, Constantinescu SN, Casadevall N, Vainchenker W, Bellanné-Chantelot C, Plo I.

Haematologica. 2018 Apr;103(4):575-586. doi: 10.3324/haematol.2017.176370. Epub 2017 Dec 21.

6.

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

Guy B, Noriega F, Ochiai RL, L'azou M, Delore V, Skipetrova A, Verdier F, Coudeville L, Savarino S, Jackson N.

Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1335201. Epub 2017 Jun 7. Review. Erratum in: Expert Rev Vaccines. 2017 Jul;16(7):ix.

PMID:
28590795
7.

Comprehensive Proteomic Analysis of Human Erythropoiesis.

Gautier EF, Ducamp S, Leduc M, Salnot V, Guillonneau F, Dussiot M, Hale J, Giarratana MC, Raimbault A, Douay L, Lacombe C, Mohandas N, Verdier F, Zermati Y, Mayeux P.

Cell Rep. 2016 Aug 2;16(5):1470-1484. doi: 10.1016/j.celrep.2016.06.085. Epub 2016 Jul 21.

8.

Comment on: PACE4 (PCSK6): another proprotein convertase linked to iron homeostasis?

Pagani A, Ladli M, Nai A, Verdier F, Camaschella C, Silvestri L.

Haematologica. 2015 Sep;100(9):e380. doi: 10.3324/haematol.2015.128348. No abstract available.

9.

Regulation of cell surface transferrin receptor-2 by iron-dependent cleavage and release of a soluble form.

Pagani A, Vieillevoye M, Nai A, Rausa M, Ladli M, Lacombe C, Mayeux P, Verdier F, Camaschella C, Silvestri L.

Haematologica. 2015 Apr;100(4):458-65. doi: 10.3324/haematol.2014.118521. Epub 2015 Jan 30.

10.

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.

D'allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, Floquet C, Dubreuil P, Lacombe C, Fontenay M, Mayeux P, Kosmider O.

PLoS One. 2013 Apr 23;8(4):e60961. doi: 10.1371/journal.pone.0060961. Print 2013.

11.

[Heart failure and anaphylactic shock. A report of two cases].

Verdier F, Petitjeans F, Griffet V, Caignault JR, Guerard S.

Ann Cardiol Angeiol (Paris). 2011 Apr;60(2):113-7. doi: 10.1016/j.ancard.2010.12.022. Epub 2011 Jan 19. French.

PMID:
21277563
12.

Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis.

Forejtnikovà H, Vieillevoye M, Zermati Y, Lambert M, Pellegrino RM, Guihard S, Gaudry M, Camaschella C, Lacombe C, Roetto A, Mayeux P, Verdier F.

Blood. 2010 Dec 9;116(24):5357-67. doi: 10.1182/blood-2010-04-281360. Epub 2010 Sep 8.

PMID:
20826723
13.

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.

Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D.

Blood. 2010 Nov 18;116(20):4240-50. doi: 10.1182/blood-2009-12-260711. Epub 2010 Jul 29.

PMID:
20671123
14.

Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone.

Chung B, Verdier F, Matak P, Deschemin JC, Mayeux P, Vaulont S.

FASEB J. 2010 Jun;24(6):2093-103. doi: 10.1096/fj.09-152561. Epub 2010 Feb 2.

PMID:
20124431
15.

[Changes in cardiovascular risk factors in developing countries].

Verdier F, Fourcade L.

Med Trop (Mars). 2007 Dec;67(6):552-8. French.

PMID:
18300515
16.

beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation.

Meyer L, Deau B, Forejtníková H, Duménil D, Margottin-Goguet F, Lacombe C, Mayeux P, Verdier F.

Blood. 2007 Jun 15;109(12):5215-22. Epub 2007 Feb 27.

PMID:
17327410
17.

Selected anti-Epo receptor antibodies predict Epo receptor expression.

Verdier F, Gomez S, Lacombe C, Mayeux P.

Blood. 2006 Aug 1;108(3):1106; author reply 1107. No abstract available.

PMID:
16861356
18.

Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation.

Cathelin S, Rébé C, Haddaoui L, Simioni N, Verdier F, Fontenay M, Launay S, Mayeux P, Solary E.

J Biol Chem. 2006 Jun 30;281(26):17779-88. Epub 2006 Apr 24.

19.

[International conference on tropical medicine "Medicine and health in the Tropics" September 11 to 15 2005. Buruli ulcer].

Verdier F, Berend M, Morand JJ.

Med Trop (Mars). 2005 Nov;65(5):423. French. No abstract available.

PMID:
16465800
20.

[Outcome of 30 congenital atrio-ventricular blocks].

Verdier F, Jimenez M, Chevalier JM, Thambo JB, Bire F, Clémenty J, Choussat A.

Arch Mal Coeur Vaiss. 2005 May;98(5):513-8. French.

PMID:
15966601
21.

Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.

Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Hunault-Berger M, Berthou C, Villemagne B, Jourdan E, Audhuy B, Solary E, Witz B, Harousseau JL, Himberlin C, Lamy T, Lioure B, Cahn JY, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Blood. 2005 Aug 1;106(3):1063-6. Epub 2005 Apr 19.

PMID:
15840695
22.

Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey.

Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E.

Vaccine. 2005 Feb 3;23(11):1359-67.

PMID:
15661384
23.

Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects.

Schleiss MR, Bernstein DI, Passo M, Parker S, Meric C, Verdier F, Newkirk MM.

Vaccine. 2004 Dec 16;23(5):687-92.

PMID:
15542191
24.

Both proteasomes and lysosomes degrade the activated erythropoietin receptor.

Walrafen P, Verdier F, Kadri Z, Chrétien S, Lacombe C, Mayeux P.

Blood. 2005 Jan 15;105(2):600-8. Epub 2004 Sep 9.

PMID:
15358619
25.

Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type.

Rimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, Sauzeat E, Fournier JG, Clayette P, Siegrist CA, Dormont D.

Vaccine. 2004 Aug 13;22(23-24):3127-35.

PMID:
15297065
26.

Reproductive toxicity testing of vaccines.

Verdier F, Barrow PC, Burge J.

Toxicology. 2003 Apr 1;185(3):213-9. Review.

PMID:
12581696
27.

Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization.

Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G, Filonenko V, Wang L, Proud CG, Parker PJ, Gout IT.

Mol Cell Biol. 2003 Feb;23(3):852-63.

28.

Ruk is ubiquitinated but not degraded by the proteasome.

Verdier F, Valovka T, Zhyvoloup A, Drobot LB, Buchman V, Waterfield M, Gout I.

Eur J Biochem. 2002 Jul;269(14):3402-8.

29.

Molecular cloning of CoA Synthase. The missing link in CoA biosynthesis.

Zhyvoloup A, Nemazanyy I, Babich A, Panasyuk G, Pobigailo N, Vudmaska M, Naidenov V, Kukharenko O, Palchevskii S, Savinska L, Ovcharenko G, Verdier F, Valovka T, Fenton T, Rebholz H, Wang ML, Shepherd P, Matsuka G, Filonenko V, Gout IT.

J Biol Chem. 2002 Jun 21;277(25):22107-10. Epub 2002 Apr 29.

30.

Non-clinical vaccine safety assessment.

Verdier F.

Toxicology. 2002 May 15;174(1):37-43. Review.

PMID:
11972990
31.

[Intrarectal administration of quinine: an early treatment for severe malaria in children?].

Barennes H, Kailou D, Pussard E, Munjakazi JM, Fernan M, Sherouat H, Sanda A, Clavier F, Verdier F.

Sante. 2001 Jul-Sep;11(3):145-53. French.

32.

Predictive value of pre-clinical work for vaccine safety assessment.

Verdier F, Morgan L.

Vaccine. 2001 Oct 15;20 Suppl 1:S21-3. No abstract available.

PMID:
11587804
33.

Recombinant viruses as a tool for therapeutic vaccination against human cancers.

Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P.

Immunol Lett. 2000 Sep 15;74(1):11-25. Review.

PMID:
10996623
34.

Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors.

Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C, Mayeux P.

J Biol Chem. 2000 Jun 16;275(24):18375-81.

35.

Quinine disposition in globally malnourished children with cerebral malaria.

Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M, Granic G, Verdier F.

Clin Pharmacol Ther. 1999 May;65(5):500-10.

PMID:
10340915
36.

Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase.

Lecoq-Lafon C, Verdier F, Fichelson S, Chrétien S, Gisselbrecht S, Lacombe C, Mayeux P.

Blood. 1999 Apr 15;93(8):2578-85.

PMID:
10194437
37.

Preclinical safety evaluation of human gene therapy products.

Verdier F, Descotes J.

Toxicol Sci. 1999 Jan;47(1):9-15. Review.

PMID:
10048148
38.

An open randomized clinical study of intrarectal versus infused Quinimax for the treatment of childhood cerebral malaria in Niger.

Barennes H, Munjakazi J, Verdier F, Clavier F, Pussard E.

Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):437-40.

PMID:
9850403
39.

Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein.

Verdier F, Chrétien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C, Mayeux P.

J Biol Chem. 1998 Oct 23;273(43):28185-90.

40.

A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.

Verdier F, Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, Muller O, Mayeux P, Lacombe C, Gisselbrecht S, Chretien S.

Mol Cell Biol. 1998 Oct;18(10):5852-60.

41.

The popliteal lymph node assay: results of a preliminary interlaboratory validation study.

Vial T, Carleer J, Legrain B, Verdier F, Descotes J.

Toxicology. 1997 Oct 19;122(3):213-8.

PMID:
9328221
42.
43.

Autoantibodies in conventional toxicity testing.

Verdier F, Patriarca C, Descotes J.

Toxicology. 1997 Apr 11;119(1):51-8. Review.

PMID:
9129195
44.

The popliteal lymph node assay in 1996.

Descotes J, Patriarca C, Vial T, Verdier F.

Toxicology. 1997 Apr 11;119(1):45-9. Review.

PMID:
9129194
45.

Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.

Chrétien S, Varlet P, Verdier F, Gobert S, Cartron JP, Gisselbrecht S, Mayeux P, Lacombe C.

EMBO J. 1996 Aug 15;15(16):4174-81.

46.

Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria.

Barennes H, Pussard E, Mahaman Sani A, Clavier F, Kahiatani F, Granic G, Henzel D, Ravinet L, Verdier F.

Br J Clin Pharmacol. 1996 May;41(5):389-95.

47.

[Effects of chloroquine on the replication of a murine retrovirus].

Sinet PM, Verdier F, Charmot G, Desforges B, Gaudin C, Pocidalo JJ.

Bull Soc Pathol Exot. 1996;89(3):175-8. French.

PMID:
8998409
48.

p53 gene mutation: software and database.

Béroud C, Verdier F, Soussi T.

Nucleic Acids Res. 1996 Jan 1;24(1):147-50.

49.

Determination of lymphocyte subsets and cytokine levels in cynomolgus monkeys.

Verdier F, Aujoulat M, Condevaux F, Descotes J.

Toxicology. 1995 Dec 20;105(1):81-90. Review.

PMID:
8638287
50.

Short report: pefloxacin does not potentiate quinine efficacy against Plasmodium falciparum malaria.

Deloron P, Aubry P, Ndayirabije A, Clavier F, Verdier F.

Am J Trop Med Hyg. 1995 Dec;53(6):646-7.

PMID:
8561268

Supplemental Content

Loading ...
Support Center